Hans Schambye, Galecto CEO

Galec­to ax­es lead can­di­date in lung dis­ease af­ter PhI­Ib miss, stock craters

Galec­to scrapped de­vel­op­ment of its lead can­di­date af­ter the drug missed the pri­ma­ry end­point in a mid-stage lung dis­ease tri­al and said it is eval­u­at­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.